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Abstract
Background: Previous studies have suggested an increasing use of complementary and alternative
medicine (CAM) in patients with inflammatory bowel disease (IBD). The aim of our study was to
evaluate the use of CAM in German patients with IBD.
Methods: A questionnaire was offered to IBD patients participating in patient workshops which
were organized by a self-help association, the German Crohn's and Colitis Association. The self-
administered questionnaire included demographic and disease-related data as well as items
analysing the extent of CAM use and satisfaction with CAM treatment. Seven commonly used CAM
methods were predetermined on the questionnaire.
Results: 413 questionnaires were completed and included in the analysis (n = 153 male, n = 260
female; n = 246 Crohn's disease, n = 164 ulcerative colitis). 52 % of the patients reported CAM use
in the present or past. In detail, homeopathy (55%), probiotics (43%), classical naturopathy (38%),
Boswellia serrata extracts (36%) and acupuncture/Traditional Chinese Medicine (TCM) (33%) were
the most frequently used CAM methods. Patients using probiotics, acupuncture and Boswellia
serrata extracts (incense) reported more positive therapeutic effects than others. Within the
statistical analysis no significant predictors for CAM use were found. 77% of the patients felt
insufficiently informed about CAM.
Conclusion: The use of CAM in IBD patients is very common in Germany, although a large
proportion of patients felt that information about CAM is not sufficient. However, to provide an
evidence-based approach more research in this field is desperately needed. Therefore, physicians
should increasingly inform IBD patients about benefits and limitations of CAM treatment.
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Background
The use of complementary and alternative medicine
(CAM) is widespread and still increasing in the Western
world [1,2]. The term complementary medicine refers to a
group of diagnostic and therapeutic disciplines that exist
largely outside the institutions where conventional health
care is provided and taught [3]. The wide range of disci-
plines classified as complementary medicine makes it dif-
ficult to find defining criteria that are common to all.
Furthermore, the diagnostic and therapeutic approaches
which are summarized among the term CAM depend on
traditions and historical developments of a country and
therefore, vary considerably among countries [4]. Also,
the extent to which CAM is practiced by physicians or
non-medical therapists differs considerably among coun-
tries. In Germany, medical doctors can obtain a variety of
additional qualifications relating to specific CAM meth-
ods (e.g. chiropractic, homeopathy) or to naturopathic
medicine in general (naturopathy). In 2004 the German
federal medical chamber documented 15.970 additional
qualifications of medical doctors in chiropractic, 5.538 in
homeopathy and 13.502 in naturopathy (= 18.5% physi-
cians working in the ambulatory sector). In addition,
about 2.5% of the ambulatory physicians are qualified in
the field of physical medicine [5]. Furthermore, around
25% of the physicians in the ambulatory sector have
passed a special training in acupuncture. In near future,
acupuncture will also be a qualification accredited by the
local medical chambers such as chiropractic or homeopa-
thy. Moreover, in Germany many physicians are provid-
ing CAM in their daily practice without having an
additional CAM qualification [6].
Other health care professionals such as pharmacists, den-
tists, physiotherapists or midwives also practise some
form of CAM. Official data on CAM qualifications for
these health care professions are not available.
Apart from the regular health care professionals Germany
has one state-regulated profession – the 'Heilpraktiker'. A
'Heilpraktiker' has to pass an examination on basic medi-
cal knowledge and skills at a local public health office to
obtain a state license. 'Heilpraktiker' only practice in the
ambulatory sector and their services are not covered by
health insurance funds. Any CAM method can be per-
formed by a 'Heilpraktiker' as long as it is consistent with
the general standards of good professional practice in
health care as supervised by the local public health office.
In general 'Heilpraktiker' provide a variety of CAM meth-
ods. Within the last ten years the number of 'Heilprak-
tiker' increased from 9.000 in the year 1993 to nearly
20.000 today.
In Germany, the overall percentage of individuals with
CAM experience increased from 52% in 1970 to 73% in
2002 [5]. A recently published national representative
sample shows that herbal medicine, exercise therapy and
hydrotherapy are the most frequently used CAM methods
[7] – all of them belonging to the so-called classic
naturopathy, also known as kneippism from its originator
Sebastian Kneipp (1821–97), a German priest. Besides the
classic naturopathic methods homeopathy, manual ther-
apy and acupuncture are commonly used CAM therapies
in Germany [7].
It is commonly known, that patients with chronic diseases
rank high among CAM users. Several surveys in patients
with IBD have shown rates of CAM utilization ranging
from 39% in Austria to 47% in Switzerland and Canada
[8-11]. A survey among German IBD patients found 51%
with experience in CAM. Homeopathy and herbal medi-
cine were the most commonly used types of CAM in this
recently published survey [12].
The purpose of our study was to estimate the extent of
CAM experience among IBD patients in Germany and to
obtain information about the most commonly used CAM
methods, about CAM providers and about perceived
effects of CAM therapy.
Methods
Participants and data collection
We surveyed IBD patients meeting at patient workshops
organized by the German Crohn's and Ulcerative Colitis
Association (DCCV e.V.). The DCCV [13] is a national
organization established by patients and for patients with
Crohn's disease (CD) and Ulcerative Colitis (UC). The
patient workshops of the DCCV take place regularly in dif-
ferent regions of Germany and are open to the public.
Normally experts are invited to give lectures on recent
developments in diagnostic and therapeutic possibilities
in order to inform patients. Three of these workshops
(which were not specific to CAM) took place in different
German federal states (Erlangen; October 1998/Aachen;
May 2000/Tübingen; June 2000). A questionnaire was
handed out to all participants of the workshops. The ques-
tionnaires were distributed on the tables in the conven-
tion hall and had to be completed during the workshop or
were to be returned by mail.
Questionnaire
The 4-page structured self-administered questionnaire
contained questions on patients' demographic data (10
items) and on characteristics of the disease such as dura-
tion of disease, current medication and satisfaction with
conventional therapy (16 items). Detailed questions were
asked about knowledge and interest in CAM and CAM use
specifically for their IBD symptoms (15 items). The items
were designed as yes/no questions or open-ended ques-
tions or to be answered on a 5-point Likert scale.BMC Complementary and Alternative Medicine 2006, 6:19 http://www.biomedcentral.com/1472-6882/6/19
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Within the questionnaire CAM was defined as 'all non-
conventional therapy methods, which are based rather on
personal experience than on a scientific basis'. Seven CAM
therapies which are commonly used in Germany were
predetermined in the questionnaire: classic naturopathic
medicine (incl. herbal medicine and hydrotherapy), Tra-
ditional Chinese Medicine incl. acupuncture (TCM),
homeopathy, Boswellia serrata (incense), probiotics, neu-
ral therapy (= pain therapy with local anaesthetics) and
anthroposophic medicine.
Patients were asked to assess the perceived therapeutic
effect of CAM treatment on a 5-point Likert scale and to
indicate where they received the CAM therapy: general
practitioner, gastroenterologist, clinician or 'Heilprak-
tiker" (= state registered non-physician CAM practitioner).
Data analysis
Data analysis was completed with SPSS (Version 9.0).
Descriptive statistics (mean and proportions) were used
to describe each variable. The chi-square test was used to
identify significant differences in CAM use regarding pos-
sible predictive patient characteristics such as age, gender,
weight, graduation level, membership of DCCV, site of
workshop, disease, current medication, smoking status,
special diets, regular exercise or type of health insurance.
Since no significant differences were found for any of
these variables during statistical analysis, data in the result
section will be presented for the complete sample only.
Due to the fact that probiotic therapy was missing on the
list of predetermined CAM methods within the Erlangen
questionnaire, the percent values for probiotic use were
calculated for the sample without Erlangen patients.
Results
Respondents
According to information given by the German Crohn's
and Ulcerative Colitis Association about 250 patients par-
ticipated at the workshop in Aachen, 250 patients in
Tübingen and about 340 patients in Erlangen (n total =
840). Altogether 413 patients completed and returned the
questionnaire which corresponds to an overall response
rate of 49% (Erlangen 61%, Aachen 35%, and Tübingen
47%). All 413 questionnaires were included in the final
analysis sample.
All in all there was a greater proportion of patients with
Crohn's disease (n = 246) than with Ulcerative Colitis (n
= 164) returning the questionnaire. 3 patients did not
indicate their diagnosis. Table 1 shows the demographic,
disease-related and treatment characteristics. Duration of
disease was 14 ys in average and patients consulted their
general practitioner about 12 times a year for their IBD.
About 80% of the patients had been hospitalised because
of IBD at least once and 39% had undergone some kind
of surgical intervention for their IBD. 45% of the patients
stated that they were satisfied with their current conven-
tional treatment: 64% of the patients receiving aminosal-
ycilates, 36% being treated with corticosteroids and 17%
taking immunosuppressive drugs (Table 1). 55% of the
IBD patients reported side-effects due to their conven-
tional treatment. 25% of the patients were on a special
diet (vegetable diet, sugar-reduced diet, whole foods etc.).
On a 5 -point Likert scale 32 % of the patients indicated
that they feel stressed or highly stressed by their disease on
a physical level and 36% on a mental level.
Comparing the three sites Erlangen (n = 207), Aachen (n
= 88) and Tübingen (n = 118) some small, however not
significant differences were found. Tübingen-patients had
been slightly less hospitalised and had undergone fewer
surgical interventions compared to patients in Erlangen
and Aachen. In addition, the application of pharmaco-
therapy, in particular aminosalicylates, was slightly lower
among Tübingen-patients.
Use and provider of CAM
52% (n = 215) of all patients reported the use of some
form of CAM to treat their IBD currently or in the past
(Table 2). The most frequently used therapy method was
homeopathy (55%), followed by probiotics (43%), classi-
cal naturopathy (38%), Boswellia-serrata extracts (36%)
and acupuncture/TCM (33%). Anthroposophic medicine
(7%) and neural therapy (5%) were applied less fre-
quently.
CAM was initiated in 40% by a general practitioner, in
29% by a practicing gastroenterologist and in 15% by a
clinician. 44% of the patients visited a so-called 'Heilprak-
tiker" for the CAM treatment. 54% of those patients, who
received CAM treatment not by their general practitioners,
informed their GP about the additional treatment with
CAM. There were no significant differences in CAM use
regarding any patient-related characteristics.
Benefit, risks and costs of CAM
Within the questionnaire patients were asked on a 5-point
Likert scale how satisfied they were regarding CAM treat-
ment for IBD. Most satisfied were patients treated with
probiotics (57%), followed by patients treated with acu-
puncture/TCM (49%) and Boswellia serrata extract (44%)
(Table 3). 15% of the CAM users notified side effects of
the CAM treatment, in general. However, the question-
naire did not assess side effects of specific CAM methods
in detail.
73% of the patients receiving CAM reported that they
financed the treatment in part or completely themselves.
Only 23% of all patients felt sufficiently informed aboutBMC Complementary and Alternative Medicine 2006, 6:19 http://www.biomedcentral.com/1472-6882/6/19
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CAM treatment in IBD. Most respondents required that
CAM should be reimbursed by the statutory health insur-
ance (96%) and that research in CAM should be increased
(97%).
Discussion
52% of the 413 patients participating in our survey
reported some form of current or previous CAM use for
their IBD. These findings correspond to results in previous
surveys in selected groups of IBD patients attending spe-
cialty clinics in North America and European countries
[8,10,11,14]. In our survey homeopathy was the most fre-
quently used CAM method, followed by probiotics, classi-
cal naturopathy (including herbal therapy), Boswellia
serrata extracts and acupuncture/TCM. However, it is dif-
ficult to compare surveys of CAM utilization among coun-
tries because the extension of specific CAM methods is
tightly linked to the traditional and cultural background
of a country. While herbal products are very popular both
in North America and in Europe, homeopathy is less used
in North America, but very popular in Europe. As
expected, the most commonly used CAM methods among
our IBD patients are comparable with data from the
neighbouring countries Austria and Switzerland [9,10]. In
both of these countries as well as in the German survey of
Langhorst et al. homeopathy was the most frequently
used CAM method [12].
Various previous surveys have indicated that CAM users
are generally more likely to be female and to be better
educated [7,15]. In our study, duration of disease, gender,
age and previous surgery/hospitalisation were not predic-
tive for the use of CAM. Nor we could confirm the find-
ings of Langhorst et al that steroid medication and
academic education are strong predictors for CAM use
[12]. Furthermore our results do not support the assump-
Table 1: Sociodemographic and disease-related characteristics of the study population.
Characteristics All Patients CAM user  CAM non-user  P value#
(n = 413) (n = 215) (n = 198)
Sex (%)
Male 38 39 37 ns
Female 62 61 63 ns
Age (%)
≤20 6 5 8 ns
2 1 – 4 0 5 65 65 6n s
4 1 – 6 0 3 23 33 0n s
≥61 6 6 5 ns
Diagnosis (%)
Crohn's Disease 61 58 65 ns
Ulcerative Colitis 39 42 35 ns
Location (% of location)
Erlangen 50 55 45 ns
Aachen 21 53 47 ns
T u e b i n g e n 2 84 95 1n s
Duration of disease 
(median)
14.0 15 13 ns
Previous hospitalisation (%) 80 82 77 ns
Previous surgery (%) 39 36 41 ns
Current Medication (%)
SASP or 5-ASA 64 54 72 ns
Corticosteroids 36 32 40 ns
Immunosuppressive 17 17 16 ns
Patient satisfaction with 
current therapy (%)
satisfied 45 43 48 ns
n e u t r a l 3 13 03 2n s
dissatisfied 19 17 20 ns
Side effects of conventional 
medication (%)
55 58 52 ns
Members of DCCV (%)* 48 47 48 ns
Academic education (%)* 23 22 24 ns
If not stated otherwise, all values are percentages of CAM users and CAM non-users resp.
# p value for the comparison of CAM users and non-users
*This item was missing for Erlangen patients.
For some items the numbers may not add up to the total number because of missing responsesBMC Complementary and Alternative Medicine 2006, 6:19 http://www.biomedcentral.com/1472-6882/6/19
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tion that our patients use CAM because of dissatisfaction
with conventional treatment or side effect profile of con-
ventional medication. This lack of CAM-predictors is in
accordance with the Swiss survey of Quattropani et al
[10]. Accordingly, due to our data IBD patients using CAM
seem not so different from non-users of CAM – at least
regarding the evaluated predictors. Nevertheless, there
may be differences between CAM users and non-users in
terms of patients' perceptions of disease, expectations
towards treatment or preferences for shared decision mak-
ing. These factors would be interesting to assess in future
surveys.
In some of the prior studies patients were asked to state
the perceived effects of CAM treatment [10,11]. In the sur-
vey of Hilsden 67% of present CAM users and 35% of
prior CAM users resp. reported beneficial effects regarding
their IBD symptoms [11]. In the Quattropani survey 61%
of the patients reported an improvement while using
CAM [10]. However, no further differentiation regarding
specific CAM methods was reported in these studies. In
our survey the perceived beneficial effects varied between
57% for probiotic therapy and 34% for treatment with
classical naturopathy incl. herbals. Although explanatory
power of this data is limited it can be regarded as an indi-
cator for patients' satisfaction with a specific CAM
method.
A strength of the study is that CAM was defined clearly
within the questionnaire and that CAM methods most
commonly used among German patients were predeter-
mined in the questionnaire. Furthermore, the survey was
based on patients participating at IBD workshops organ-
ized by a self-help association but open for public. In con-
trast, most of the previous studies only included patients
visiting special IBD clinics [8,11,14]. We therefore sur-
veyed a less pre-selected collective. However, it was not a
non-random sample and therefore a bias can not be
excluded, because our population may still not be in con-
formity with the general IBD population, as 46% of the
surveyed patients were members of the self-help associa-
tion DCCV. Those patients may have different strategies to
manage their disease. For example, they might take more
responsibility for their health-care and the management
of their treatment. The study may therefore overestimate
the use of CAM among IBD patients.
A limit of our study is that the response rate only could be
estimated retrospectively, since the questionnaires were
not handed out personally to each patient. It may be pos-
sible that some patients did not recognize the question-
naires or that patients interested in CAM rather tended to
complete the questionnaire than patients not interested in
CAM leading to a possible selection bias. However, this
argument may be invalidated by a comparison of our
results with the study of Langhorst et al. who surveyed a
randomly drawn sample of German IBD patients [12]. We
found high corresponding results regarding CAM use
(52% vs. 51%) and the high popularity of homeopathy
(53% vs. 55%).
The most common CAM therapy used by patients in our
survey was homeopathy. This finding might be influenced
by the fact that homeopathy was established by S. Hahne-
mann, a German physician. Since homeopathic treatment
is not reimbursed by the statutory health insurance,
Table 2: Previous or present use of CAM
Patients using CAM
Classical naturopathy n (% of CAM users) 82 (38 %)
Boswellia serrata n (% of CAM users) 78 (36 %)
Probiotics n (% of CAM users) 44 (43 %)*
Acupuncture/TCM n (% of CAM users) 70 (33 %)
Homeopathy n (% of CAM users)1 1 9  ( 5 5  % )
* calculated for n = 102 CAM users, because this item was missing in the Erlangen questionnaire.
Table 3: Subjective rating of the efficacy of CAM treatment
Satisfied with CAM treatment  No change  Unsatisfied with CAM 
treatment 
n (%) n (%) n (%)
Classical naturopathy (n = 82) 28 (34%) 17 (21%) 30 (37%)
Boswellia serrata extract (n = 78) 34 (44%) 9 (12%) 21 (27%)
Probiotics (n = 44) 25 (57%) 6 (14%) 7 (16%)
Acup./TCM (n = 70) 34 (49%) 15 (21%) 14 (20%)
Homeopathy (n = 119) 47 (39%) 28 (24%) 42 (35%)BMC Complementary and Alternative Medicine 2006, 6:19 http://www.biomedcentral.com/1472-6882/6/19
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homeopathic therapies often are self initiated by the
patients, provided by 'Heilpraktiker' or by homeopaths
(physicians with the additional qualification 'homeopa-
thy') in private practice. Unfortunately, in our survey we
did not ask which CAM therapy was administered by
which type of practitioner or which CAM therapy was self
initiated by the patient resp. Perceived effects of the home-
opathic treatment were less positive compared to the
other CAM methods. Interestingly, in a Medline search no
clinical study assessing the efficacy of homeopathic prep-
arations in patients with IBD could be found.
Our data shows a frequent use of probiotics. This may be
the consequence of several recently published clinical
studies with probiotic preparations in the treatment of UC
and CD [16-18]. According to the positive results of those
studies the usage of probiotics for maintenance of remis-
sion is recommended in the updated guideline for Diag-
nosis and Therapy of Ulcerative Colitis by the German
Society of Digestive and Metabolic Disease and the Com-
petence Network of IBD [19]. Therefore, in Germany pro-
biotic therapy can be prescribed for the treatment of IBD
and will be paid for by the statutory health insurance.
Despite implementation of probiotics in the national
guideline, this therapy is originated from the field of CAM
and it is therefore an excellent example for an evidence-
based integration of CAM into conventional treatment.
Acupuncture/TCM was also frequently used by our IBD
patients. Considering the popularity of acupuncture the
high number of physicians with an additional training in
acupuncture therapy in Germany is not surprising. More-
over, also many 'Heilpraktiker' provide acupuncture. Nev-
ertheless, at present there are only a few observational
studies on the effect of acupuncture in UC [20,21] and
one single randomised, controlled study in MC patients
[22]. MC patients showed a decrease of disease activity as
well as an improvement in quality of life after acupunc-
ture treatment in this study.
One third of our patients reported a therapeutic approach
with Boswellia serrata extracts/incense. Preparations from
the gum resin of Boswellia serrata have been used as a tra-
ditional remedy in Ayurvedic medicine in India for the
treatment of inflammatory diseases. In clinical trials
promising results were observed in patients with rheuma-
toid arthritis, inflammatory bowel disease and bronchial
asthma, but to date results from larger randomised con-
trolled studies are missing [23-25]. The therapeutic
approaches with Boswellia serrata may have been self ini-
tiated by the patients or recommended by 'Heilpratiker'.
55% of the patients reported side effects on their conven-
tional medication and 20% were completely dissatisfied
with their current conventional treatment. According to
previous studies this might be the main reason for IBD
patients to enter CAM treatment [8]. Side effects of CAM
therapy were described by 14% of our IBD patients.
Unfortunately, the questionnaire provided no further
information about type or severity of the perceived CAM
side effects. Only 23% of the IBD patients in our survey
felt sufficiently informed about CAM.
Conclusion
Physicians should address their patients straightforward
regarding CAM and offer evidence-based information
about specific CAM methods. On the basis of available
scientific data they should aim at guiding patients through
the 'CAM jungle'. At the same time, further clinical studies
assessing the most commonly used CAM therapies are
urgently needed. Research in CAM offers the chance to
discover new treatment options in the management of
IBD but may also protect patients from ineffective and
expensive 'pseudo'-therapies.
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